Press coverage about Syros Pharmaceuticals (NASDAQ:SYRS) has been trending somewhat positive on Thursday, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.3039413944154 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Several equities analysts have weighed in on the company. BidaskClub raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 22nd. HC Wainwright reissued a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, March 14th. Wedbush reissued an “outperform” rating and set a $13.00 price target (up previously from $11.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, March 13th. Zacks Investment Research downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 price target for the company. in a research report on Saturday, January 20th. Finally, Oppenheimer set a $28.00 price objective on Syros Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $21.13.
Syros Pharmaceuticals stock traded down $0.13 during midday trading on Thursday, reaching $12.40. The stock had a trading volume of 105,499 shares, compared to its average volume of 243,656. The stock has a market capitalization of $411.76, a P/E ratio of -5.82 and a beta of -2.83. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38.
In related news, Director Srinivas Akkaraju acquired 209,424 shares of Syros Pharmaceuticals stock in a transaction on Wednesday, January 31st. The shares were bought at an average price of $9.55 per share, for a total transaction of $1,999,999.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 33.60% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.